Meta-analytic review of the clinical effectiveness of oral deferiprone (L1)

European Journal of Clinical Pharmacology

Volumn 55, Issue 1, 1999, Pages 1-6

  Addis, A ^a,b,c   Loebstein, R ^c   Koren, G ^c   Einarson, T R ^b  

^a Lab for Mother and Child Health   (Italy)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Deferiprone; Iron overloaded patients; Meta analysis

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN;

DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FERRITIN BLOOD LEVEL; HUMAN; IRON CHELATION; IRON OVERLOAD; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, ORAL; DRUG EVALUATION; FERRITINS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; PYRIDONES;

EID: 0033034080     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050584     Document Type: Review

References (26)

1. Brittenham GM, Griffith PM, Nienhuis AW, MCLaren CE, Young NS, Tucker EE, Allen CJ, Farrel DE, Harris JW (1994) Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 331: 567-573
2. Olivieri NF, Nathan DG, MacMillan JH, Wayne AD, Martin M, MCGee A, Koren G, Liu P, Cohen AR (1994) Survival of medically treated patients with homozygous beta thalassemia. N Engl J Med 331: 574-578
3. Gabutti V, Piga A (1996) Results of long-term iron-chelating therapy. Acta Haematol 95: 26-36
4. Olivieri NF, Buncic R, Chew E, Gallant T, Harrison R, Keenan N, Logan W, Mitchell D, Ricci G, Skarf B, et al. (1986) Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 314: 869-873
5. Olivieri NF, Brittenham GM, Armstrong SAM, Barsran RK, Daneman R, Daneman N, Iwanchko RM, Talbot AL, Koren G (1995) First prospective randomized trial of the iron chelators deferiprone and deferoxamine. Blood 86: 249A
6. Diav-Citrin O, Koren G (1997) Oral iron chelation with deferiprone. Pediatr Clin North Am 44: 235-247
7. Hoffbrand AV (1996) Oral iron chelation. Semin Hematol 33: 1-8
8. Agarwal MB (1993) Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1). Indian J Pediatr 60: 509-516
9. Rosenthal R (1984) Meta-analytic procedure for social research. Sage, Beverly Hills, CA
10. Wolf FM (1986) Meta-analysis: quantitative methods for research synthesis. Sage Beverly Hills, CA
11. Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy A, Hirt A, Hoffbrand AV, Lottenbach AM, Sonderegger T, Wagner HP (1990) L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. Br J Haematol 76: 550-553
12. Goudsmit R, Kersten MJ (1992) Long-term treatment of transfusion hemosiderosis with the oral iron chelators L1. Drugs Today 28[suppl A]: 133-135
13. Jaeger M, Aul C, Sohngen D, Germing U, Schneider W (1992) Iron overload in polytransfused patients with MDS: use of L1 for oral iron chelation. Drugs Today 28 [Suppl A]: 143-147
14. Al-Refaie FN, Hoffbrand AV (1994) Oral iron-chelating therapy: the L1 experience. Baillieres Clin Haematol 7: 941-963
15. Carnelli V, Terzoli S, Fossati G, Careddu G, Perri M, Pedrotti L, Mirra N (1992) New therapeutic trends in thalassemia: oral chelating agents. Pediatr Med Chir 14: 273-275
16. Collins AF, Fassos FF, Stobie S, Lewis N, Shaw D, Fry M, Templeton DM, MCClelland RA, Koren G, Olivieri NF (1994) Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 83: 2329-2333
17. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, Sheppard L (1987) Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. BMJ 295: 1509-1512
18. Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, Goddard JG, Sheppard L, Barr J, Nortey P (1990) Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron Chelation and Metabolic Studies. Br J Haematol 76: 295-300
19. Olivieri NF, Koren G, St Louis P, Freedman MH, MCClelland RA, Templeton DM (1990) Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients. Semin Hematol 27: 101-104
20. Olivieri NF, Koren G, Hermann C, Bentur Y, Chung D, Klein J, St Louis P, Freedman MH, MCClelland RA, Templeton DM (1990) Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 336: 1275-1279
21. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, MCClelland RA, Liu PP, Templeton DM, Koren G (1995) Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 332: 918-922
22. Olivieri NF, Matsui D, Liu PP, Blendis L, Cameron R, MCClelland RA, Templeton DM, Koren G (1993) Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients. Bone Marrow Transplant 12 [Suppl 1]: 9-11
23. Al-Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorghes GJ (1992) Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood 80: 593-599
24. Kontoghiorghes GJ, Bartlett AN, Sheppard L, Barr J, Nortey P (1995) Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes. Arzneimittelforschung 45: 65-69
25. Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N, Puniyani RR, Chhablani AT (1992) Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 82: 460-466
26. Nielsen P, Fischer R, Engelhardt R, Tondury P, Gabbe EE, Janka GE (1995) Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone. Br J Haematol 91: 827-833